O cular angiogenesis, the pathologic growth of new blood vessels in the eye, is a leading cause of blindness worldwide. Neovascularization is responsible for many severe ocular disorders, such as corneal conjunctivalization, neovascular glaucoma, diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. 1, 2 The control of ocular neovascularization would be promising for the treatment of these disorders. Similar to the well-known angiogenic mechanism in tumor growth, neovascularization in the eye is also considered to result from an imbalance between stimulatory and inhibitory angiogenic factors. 3, 4 The elevated expression of stimulatory factors and/or the downregulation of inhibitory factors is often observed in pathologic conditions such as ocular inflammation and ischemia. [5] [6] [7] [8] In contrast to these pathologic conditions, ocular tissues are maintained physiologically without the occurrence of neovascularization, and vasculature in the eye is highly restricted despite the presence of many angiogenesis-stimulating molecules in the eye, such as basic fibroblast growth factor (bFGF), 9, 10 insulin-like growth factor (IGF)-1, 11 and vascular endothelial growth factor (VEGF). 12, 13 These findings suggest the physiological existence in the eye of angiogenesis inhibitors to counterbalance these stimulators. Potent inhibitory factors have been thought to exist in the retinal pigment epithelium (RPE), 14 the vitreous body, [15] [16] [17] [18] [19] and the lens, 20 although most of them have not been isolated yet. Up to date, pigment epithelium-derived factor (PEDF), a neurotrophic factor and a member of the serine protease inhibitor superfamily, has been identified as a major angiogenesis inhibitor in the eye. [21] [22] [23] Recently, we demonstrated that chondromodulin (ChM)-I, a ϳ25-kDa glycoprotein purified as a cartilage-derived chondrocyte growth factor, 24 is another angiogenesis inhibitor specifically expressed not only in the cartilaginous tissues but also in the eye. [25] [26] [27] [28] ChM-I is expressed in the ciliary body, the ganglion cell layer of the retina, and the RPE, 27, 28 and suppresses proliferation and capillary formation of retinal vascular endothelial cells in vitro and angiogenesis in vivo. 25,28 -30 Recently, three independent groups reported the identification of a novel gene, tenomodulin (TeM; also referred to as ChM-IL or tendin), which is homologous to ChM-I. [31] [32] [33] TeM is a glycoprotein with significant amino acid sequence homology (36%) with the ChM-I precursor. 31, 32 Cloning of the full-length cDNA of TeM revealed that the TeM protein (317 amino acid residues) has a single transmembrane domain in the N-terminal region, two N-linked glycosylation sites, and a cysteine-rich domain (Phe 225 -Val 317 ) in the C-terminal region. [31] [32] [33] TeM and ChM-I exhibit the strongest sequence identity (65%) within the C-terminal 63-amino-acid stretch, which corresponds to the predicted antiangiogenic functional domain of ChM-I (Phe 272 -Val 334 ). 32 Both TeM and ChM-I carry eight cysteine residues in their C-terminal domains, and the spacing of the eight cysteine residues in TeM is almost identical with that in ChM-I. 31, 32 However, in contrast to ChM-I, the mature form of which is a secreted protein existing in the extracellular matrix after being processed from the transmembrane-type precursor, 24 TeM is a transmembrane protein presumably located at the cell surface, because it lacks the hormone-processing signal present in the ChM-I precursor. 31, 32 TeM mRNA has been demonstrated to be specifically expressed in hypovascular connective tissues such as the tendon and ligament. 32, 33 Because of the similarity in the C-terminal characteristics between TeM and ChM-I and the structural analogy noted between skeletal connective tissues and the eye in hypovascularity and components of the extracellular matrix, it can be speculated that TeM also participates in maintenance of the avascular condition in the eye.
In the present study, we investigated the gene expression of TeM in the eye by Northern blot analysis and in situ hybridization and the localization of its protein by Western blot and immunohistochemical analysis. To elucidate the antiangiogenic potential included in the C terminus of TeM and ChM-I, soluble TeM and ChM-I were produced through adenoviral gene transduction into human vascular endothelial cells, and angiogenesis assays were conducted in cell cultures.
MATERIALS AND METHODS

Tissues Preparation and Cell Culture
All experiments were conducted in accordance with the Animal Care and Use Committee guidelines and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. DDY mice, an albino mouse strain with no pigmentation in the RPE, were anesthetized with diethyl ether and killed by cutting the axillary artery. Systemic organs (eye, liver, skin, and thymus) were removed from 4-week-old mice. Embryos were collected at postcoital days 12.5 and 16.5.
Human retinal vascular endothelial cells (HRECs) and human umbilical vein endothelial cells (HUVECs) were purchased from Applied Cell Biology Research Institute (Kirkland, WA) and grown in complete medium with supplements (EGM2; Clonetics, Walkersville, MD). Cells at passages 3 through 6 were used for the experiments. Within these passages, both HRECs and HUVECs maintained their endothelial characteristics, such as the cobblestone-like morphogenesis, Ac-LDL uptake and the tubelike morphogenesis on collagen gel and expressed vascular endothelium-specific marker such as platelet-endothelial cell adhesion molecule (PECAM; CD31) on the cell surfaces. The 293 cell line, a human embryonic kidney cell line constitutively producing the adenovirus E1 protein, 34 was purchased from the American Type Culture Collection, Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS).
Northern Blot Analysis
Total cellular RNA was purified from organs of 4-week-old mice by a modified acid guanidium thiocyanate phenol-chloroform extraction method. 35 Total RNA (20 g) was denatured and transferred onto membranes (Nytran; Schleicher & Schuell, Dassel, Germany). A Northern blot containing 2 g of poly(A) ϩ RNA isolated from mouse embryos at different developmental stages was used (Clontech Laboratories Inc., Palo Alto, CA). Hybridization of the blots was performed at 42°C overnight with radiolabeled probes, using the appropriate cDNA fragments, as previously described: a 460-bp EcoRI fragment as a probe for TeM and a 1.3-kb EcoRI fragment as a probe for ChM-I. 32, 36 After hybridization, the membrane filter was washed at 55°C at high stringency and exposed to autoradiographic film (Biomax; Eastman Kodak, Rochester, NY) at Ϫ80°C.
RT-PCR Analysis
Total RNA was purified from eye tissues of 4-week-old mice and reverse transcribed (Superscript Pre-amplification System; Gibco BRL, Grand Island, NY). 31, 35 The cDNAs were amplified for 25 cycles (30 seconds at 94°C, 45 seconds at 58°C, and 60 seconds at 72°C) using mouse TeM-specific primers (forward primer: 5Ј-GAA ACC ATG GCA AAG AAT CCT CCA GAG-3Ј; reverse primer: 5Ј-TTA GAC TCT CCC AAG CAT GCG GGC-3Ј). Glyceraldehyde-3-phosphate dehydrogenase (G3PDH)-specific primers (forward primer: 5Ј-TCC TGC ACC ACC  AAC TGC TTA GC-3Ј; reverse primer: 5Ј-TTA CTC CTT GGA GGC  CAT-3Ј) were used as a positive control. PCR products were electrophoresed and visualized by ethidium bromide staining.
In Situ Hybridization
Embryos at postcoital day 16.5 and tissues from 4-week-old mice were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB) overnight, embedded in paraffin, and sectioned at a thickness of 6 m. In situ hybridization was performed as previously described. 32 In brief, a 1.0-kb fragment of mouse TeM or ChM-I cDNA subcloned into a vector (pCRII TA; Invitrogen, San Diego, CA) was used as a template for in vitro transcription after linearization of the plasmid. Digoxigenin (DIG)-labeled antisense and sense riboprobes were prepared with a DIG RNA labeling kit (Roche Molecular Biochemicals, Gaithersburg, MD). After dewaxing and rehydration, hybridization was performed at 50°C for 16 hours, and the sections were washed under conditions of high stringency. Hybridization signals were detected immunohistochemically by an alkaline phosphatase-conjugated antibody, according to the supplied instructions. The alkaline phosphatase substrate (5-bromo-a-chloro-3-indolyl phosphate/nitroblue tetrazolium [BCIP/ NBT]) was used for color detection. Sections were counterstained with purified methyl green (Laboratory Vision Co., Fremont, CA), mounted on coverslips, and photographed.
Immunohistochemistry
Both frozen and paraffin-embedded tissues of embryos at postcoital day 16.5 were prepared. For frozen sections, tissues were fixed with 4% paraformaldehyde in 0.1 M PB for 4 hours followed by immersion in 25% sucrose in PBS overnight. The tissues were embedded in optimal temperature cutting compound (Tissue-Tek; Miles, Elkhart, IN), frozen in liquid nitrogen, and sectioned at 6 m with a cryostat at Ϫ20°C. Paraffin sections were deparaffinized in xylene and treated with 1% hydrogen peroxide in methanol for 30 minutes to minimize endogenous peroxidase activity. Frozen sections were also treated with 1% hydrogen peroxide in methanol for 30 minutes to minimize endogenous peroxidase activity. Affinity-purified rabbit polyclonal anti-TeM antibody was raised against a synthetic polypeptide corresponding to amino acids 245-252 of mouse and human TeM (a kind gift from Hitoshi Wada, Teijin Institute for Biochemical Research, Teijin, Ltd. Tokyo, Japan). 32 After a wash in PBS, the sections were incubated with 0.5% normal goat serum and 1% BSA in PBS and then with the affinitypurified rabbit polyclonal anti-TeM antibody at 4°C overnight. For the control, normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) was used as the primary antibody. Immunoreactions were performed with an avidin-biotin complex (ABC) kit (Vectastain Elite; Vector Laboratories, Burlingame, CA). Sections were washed with PBS, and antigenic sites were demonstrated by treating the sections with 0.05% 3,3Ј-diaminobenzidine tetrahydrochloride (Dojin Chemicals, Tokyo, Japan) in 0.05 M Tris-HCl buffer (pH 7.6), and 0.01% H 2 O 2 . Sections were counterstained with the purified methyl green (Laboratory Vision Co.), mounted on coverslips, and photographed.
Western Blot Analysis
For detection of the natural form of TeM, mouse tissue extracts (whole eye and liver) were homogenized in homogenizing buffer (8 M urea, 50 mM Tris-HCl [pH 8.0], 1 mM dithiothreitol, and 1 mM EDTA) and centrifuged to remove the cellular debris. Aliquots (ϳ200 g of total protein) of the supernatants were diluted in 2ϫ SDS sample buffer (100 mM Tris-HCl, pH 6.8), 4% SDS, 10% ␤-mercaptoethanol, and 20% glycerol), separated on a 12.5% gel by SDS-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane. The membrane was preincubated with blocking buffer and probed with the polyclonal anti-TeM antibody at 4°C overnight. After a wash with PBS, the membrane was incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibody (Amersham Pharmacia Bio-tech, Piscataway, NJ). Protein was visualized by the enhanced chemiluminescence system (ECL Plus; Amersham Pharmacia Biotech) according to the supplied instructions.
For detection of the recombinant protein expressed in the conditioned medium, HRECs, with or without adenoviral transduction, were plated on gelatin-coated culture plates (Costar; Corning, Inc., Corning, NY) and incubated for 48 hours. The culture medium was then harvested and eluted through a separation column (butyl-Toyoperl; Tosoh Co., Tokyo, Japan). After evaporation and dilution in SDS sample buffer, Western blot was performed as described earlier. The membrane was probed with an anti-FLAG monoclonal antibody (SigmaAldrich, St. Louis, MO), followed by an HRP-conjugated anti-mouse IgG antibody (Amersham Pharmacia Biotech). The peroxidase activity was visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech).
Expression Cassette Construction
Before preparation of the recombinant adenoviral vector, an expression cassette for generating an FLAG-tagged secreted form of the recombinant protein containing residues Glu 202 -Val 317 of human TeM, corresponding to the residues Glu 215 -Val 334 of the mature form of human ChM-I, was constructed. In brief, a cDNA fragment encoding the secretion signal of preprotrypsin and the FLAG epitope from pFLAG-CMV1 (Sigma-Aldrich) was constructed in an expression plasmid. The plasmid was flanked by the SwaI site and contained the strong CAG (cytomegalovirus immediate-early enhancer-chicken ␤-actin hybrid) promoter, an internal ribosome entry site (IRES) followed by enhanced green fluorescence protein (EGFP), and a polyadenylation signal of the rabbit ␤-globin gene. 37 Then, the cDNA fragment encoding residues Glu 202 -Val 317 of human TeM generated by PCR (forward primer: 5Ј-GAG GGA GAA GAT CTT CAC TTT CC-3Ј; reverse primer: 5Ј-AAT TAA CCC TCA CTA AAG GG-3Ј) was cloned into the plasmid to create a CAG promoter/FLAG-humanTeM(Glu 202 -Val 317 )/IRES-EGFP expression cassette. Thus, a secreted form of TeM including the predicted functional domain of TeM was constructed. For comparison, a cDNA fragment encoding the mature form of human ChM-I was generated (forward primer: 5Ј-GAA GTG GTA AGA AAA ATT GTT CC-3Ј; reverse primer: 5Ј-GCG CGG CCG CTC ACT CCA TGC CCA AGA TAC GGG C-3Ј) and cloned into the expression plasmid described above to also create a CAG promoter/FLAG-humanChM-I(Glu 215 -Val 334 )/IRES-EGFP expression cassette. The FLAG-tagged secreted form TeM (fsTeM) and the FLAG-tagged mature form ChM-I (f-mChM-I) expression cassettes were excised by digestion with SwaI and ligated with the E1-defective adenoviral genome containing cosmid vector (pALC3.0), respectively. For introduction of the cosmids into Escherichia coli, an in vitro phage packaging kit (Stratagene, La Jolla, CA) was used according to the supplied instructions. The structure of the resultant cosmid vectors is illustrated later. An empty vector without the insertion but able to generate the EGFP protein through the IRES was used as the mock control in the present study.
Adenovirus Production
The method for the replication-defective E1-recombinant adenoviral vector preparation has been described previously. 38 To generate infectious recombinant adenoviral vectors, 1 g of the indicated expression cosmid and 0.1 g of pMC1-Cre for the expression of Cre recombinase were cotransfected into 293 cells, with transfection reagent (Lipofectamine 2000; GibcoBRL) used according to the supplied instructions. Cytopathic effect (CPE) in the cotransfected 293 cells was visible within 10 days. Culture media with CPE was harvested and centrifuged to obtain the supernatant fraction, which contained the adenoviral vector. After addition of the supernatant to 293 cells grown at a large scale and cultured for a further several days, 293 cells with complete CPE were harvested, lysed by six cycles of freezing and thawing, and centrifuged at 3500 rpm for 10 minutes at 4°C. The supernatant fraction, which contained the adenoviral vector, was used for evaluation of the efficiency of adenoviral vector generation and transfection according to the standard procedure described previously. 39 Manipulations of adenoviral vectors were performed in accordance with both institutional and national biosafety restrictions. For the prevention of adenovirus-induced cytotoxicity, the titer was determined that could cause apoptotic cell death within 6 to 8 passages in the cells infected with the mock vector.
Dil-Ac-LDL Uptake
To confirm the maintenance of vascular endothelial characteristics after adenoviral transduction, an Ac-LDL uptake assay was performed in the untransfected HRECs (wild type) and in the HRECs infected with the indicated adenoviral vectors. Cells were incubated with 10 g/mL Dil-Ac-LDL (Molecular Probes, Leiden, The Netherlands) in complete medium (EGM2; Clonetics) for 6 hours and further incubated with 10 nM Hoechst 33342 (Sigma-Aldrich) for 2 hours. Dil-Ac-LDL uptake in living cells was examined and photographed and the images merged with a fluorescence microscope coupled to an imaging computer system (Carl Zeiss, Oberkochen, Germany).
HREC Proliferation
DNA synthesis measured by 5Ј-bromo-2Ј-deoxyuridine (BrdU) incorporation was performed as an index of cell proliferation. Gene-transfected or wild-type early-passage (passages 3-6) HRECs were harvested with trypsin/EDTA and suspended in medium (EGM2; Clonetics) at a density of 50,000 cells/mL. The cells were seeded in a 96-well gelatincoated plate (100 L per well) and grown to subconfluence. The cells were then starved in 0.5% FBS-containing DMEM for 6 hours and stimulated with VEGF (R&D Systems, Minneapolis, MN) at the indicated concentration for another 12 hours. After the stimulation, 10 L 10ϫ BrdU was added to each well, and the cells were further incubated for 4 hours. BrdU ELISA chemiluminescence was analyzed according to the manufacturer's protocol (Roche Molecular Biochemicals).
To investigate the bioactivity of f-sTeM and f-mChM-I in the conditioned media from HRECs, HUVECs were grown to subconfluence in a 96-well culture plate, and starved in 0.5% FBS-containing ␣MEM for 6 hours. The conditioned media obtained from the wild-type HRECs or the HRECs with the indicated adenoviral gene transduction were harvested from 3-day cultures and mixed with fresh DMEM at a ratio of 1:1, to contain final concentrations of 30 ng/mL VEGF. The mixed medium was used for incubation of the serum-starved HUVECs for 12 hours, and DNA synthesis was evaluated by BrdU incorporation, according to the manufacturer's protocol (Roche Molecular Biochemicals).
In Vitro Angiogenesis Assay
For the capillary-like formation assay, growth factor-reduced synthetic matrix (Matrigel; BD Labware, Bedford, MA) was applied to a 24-well tissue culture plate (400 L per well). After a 30-minute polymerization of the matrix at 37°C, HRECs that had been serum-starved for 4 hours were harvested by using trypsin/EDTA and suspended in culture medium for 20 minutes. Cells were resuspended in migration buffer (␣MEM/0.1% BSA) and finally seeded at a density of 10,000 cells per well (final volume, 500 L) on polymerized matrix (Matrigel; BD Labware) in the presence of VEGF (10 ng/mL). The plate was incubated at 37°C for 6 hours and then photographed. For quantitative evaluation of the capillary-like morphogenesis of HRECs, four fields per well were automatically and randomly selected for digital photography, based on the computer program, and the identity of the contents of wells was masked during photography and analysis. The total length of tubelike structures per field was measured on computer with an image-processing and -analysis program (NIH image version 1.61, available by ftp from zippy.nimh.nih.gov/or from http://rsb.info.nih.gov/ nih-image; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD). Each experiment was performed three times, and the data were analyzed statistically with one-way analysis of variance (ANOVA), followed by the Scheffé multicomparison test.
To investigate the bioactivity of f-sTeM and f-mChM-I in the conditioned media from HRECs, a commercially available in vitro angiogenesis assay kit comprising cocultures of HUVECs and human dermal fibroblasts was purchased from TCS Biologicals (Buckinghamshire, UK) and used according to the supplied instructions. 40 The conditioned media from the wild-type HRECs or the HRECs with the indicated adenoviral gene transduction were harvested from the 3-day cultures and mixed with fresh DMEM at a ratio of 1:1 to obtain final concentrations of 10% FBS and 10 ng/mL VEGF. The mixed medium was used for incubation of the cocultures for 11 days. The cells were then fixed with 70% ethanol and incubated with diluted anti-human PECAM (CD31) antibody (Kurabo Inc., Osaka, Japan) for 1 hour followed by a 1-hour incubation with an alkaline phosphatase-conjugated secondary antibody. Visualization of the capillary structures formed by HUVECs was achieved with BCIP/NBT, and the total length of the capillary structures per field was measured and analyzed as described earlier.
RESULTS
Expression of TeM mRNA and TeM Protein
The pattern of TeM mRNA expression during mouse development was investigated with a blot containing RNA isolated from four different developmental time points. Northern hybridization analysis showed that the 1.4-kb transcripts for TeM were expressed at postcoital days 15 and 17 but were undetectable on or before day 11 (Fig. 1A) . Therefore, embryos at day 16.5 were collected and sectioned for in situ hybridization to identify the precise sites for TeM mRNA expression at the embryonic stage. Tissue distribution of TeM transcripts in 4-week-old mice was also evaluated by Northern blot analysis (Fig. 1B) . TeM mRNA was detected in whole eye and skin, but was detectable neither in the thymus, where ChM-I was abundantly expressed, nor in the liver. To further investigate the distribution of TeM mRNA in mouse eyes, RT-PCR was conducted and revealed that TeM mRNA was significantly expressed in the cornea, the sensory retina, and the sclera involving the ocular muscles and faintly expressed in the choroidal tissues, including the RPE (Fig. 1C) .
Western blot analysis showed that the endogenous TeM proteins were detected as double bands of 40 and 45 kDa in tissue extracts from whole eyes but were undetectable in extracts from liver (Fig. 2) . TeM proteins were also undetectable in the tissue extracts from thymus (data not shown).
In Situ Hybridization and Immunohistochemistry
In the horizontal sections through the optic stalk of the eyeball of a day-16.5 embryo (Fig. 3A) , TeM mRNA expression was detected in the tendon of extraocular muscle, the sclera (Fig.  3B) , the lens epithelial cells at the equator, and the earlydifferentiating secondary lens fiber cells (Fig. 3C) . In contrast, no apparent hybridization signals were found in the lens when hybridized with the sense probe (Fig. 3F) . TeM protein was most abundant in the differentiated secondary lens fibers (Fig.  3D ) just adjacent to lens fiber cells that expressed TeM mRNA. 
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In the early-developing retina, TeM protein was detected in RPE and the inner neural retina (Fig. 3E) . No immunostaining was observed when semiserial sections were incubated with normal rabbit IgG (Figs. 3G, 3H) . Analyses of TeM expression and localization in 4-week-old mice were also conducted. In situ hybridization revealed TeM mRNA expression in the stromal layer of the cornea and the sclera, and faint but significant expression in the ganglion cell layer of the retina and the inner nuclear layer cells (Figs. 4A,  4C, 4E ). No apparent hybridization was found in these sites when hybridized with the sense probe (Figs. 4B, 4D, 4F ).
Construction of f-sTeM-and f-mChM-I-Expressing Adenoviral Vectors
We applied a Cre-loxP recombination system to generate adenoviral vectors for expressing FLAG-tagged soluble form TeM and ChM-I proteins, designated as f-sTeM and f-mChM-I, respectively. Because the backbone of the pALC3.0 cosmid vector was constructed by replacing the E1 region of the circular form of the adenoviral genome with the loxP-flanked cosmid cassette, cotransfection of a Cre-expression plasmid with the indicated pALC3.0 cosmid vector into 293 cells efficiently generates a recombinant adenoviral vector that contains the indicated expression cassette, but lacks the cosmid vector backbone. In our experiments, fluorescence microscopic examination revealed that in the presence of Cre recombinase, CPE appeared in all wells of the transfected 293 cells within 8 days of cultures. Because recombinant adenoviruses with a titer lower than 1 ϫ 10 4 plaque-forming units (pfu)/cell did not cause apoptotic cell death in infected cells within 6 to 8 passages, infection of recombinant adenoviruses to culture cells for biological assay was performed at a multiplicity of infection (moi) of less than 2 ϫ 10 3 pfu/cell to prevent cytotoxicity. In the present study, adenoviral vectors were designed to secrete the f-sTeM protein or the f-mChM-I protein through the secretion signal of preprotrypsin. Schematic structures of human TeM and the human ChM-I precursor and the construction maps for the indicated adenoviral vectors are shown in Figures 5A and 5B. The efficiency of adenoviral FIGURE 3. Expression of TeM mRNA and TeM protein in eye of mouse embryos. In a section of the developing eye in the day-16.5 embryos, the boxed areas with significant hybridization signals (blue-violet) in (A) are shown at higher magnification in (B) and (C). TeM mRNA was expressed in the developing tendon of extrinsic ocular muscle (B), the sclera (B; arrowheads), the equatorial lens epithelial cells (C), and the early-differentiating lens fiber cells. Strong immunoreactivity (yelloworange) was found in the differentiated secondary lens fiber (D). In the developing retina, TeM protein was localized to the sclera (E), RPE (E), and the inner neural retina (E; arrowheads). In situ hybridization of a semiserial section hybridized with the sense probe showed no signals in the lens (F). No immunostaining was observed when rabbit IgG was used as the primary antibody (G, H). The sections were counterstained with methyl green. cj, conjunctiva; co, cornea; l, lens; mu, developing tendon of extraocular muscles; nr, neural retina; od, optic disc; sc, sclera; eo, extrinsic ocular muscle; le, lens epithelium; lf, lens fiber cells; rpe, RPE. Positive signals of TeM mRNA were observed in the stromal layer of the cornea (A) and sclera (E). In the retina, positive signals were detected in the ganglion cell layer (C, arrows), inner nuclear layer (C, large arrowheads), and, faintly, in the RPE (C, small arrowheads). The sections were counterstained with methyl green. ep, epithelial cell layer; st, stromal layer; en, endothelial cell layer; gcl, ganglion cell layer; ipl, inner plexiform layer; inl, inner nuclear layer; opl, outer plexiform layer; onl, outer nuclear layer; os, outer segments; rpe, RPE; ch, choroidal layer; sc, sclera. Scale bars: (A, B) 250 m; (C-F) 100 m.
transfection was monitored by the EGFP fluorescence. Almost 100% of the HRECs were successfully infected with the adenovirus (Fig. 5C ). The EGFP fluorescence in the gene-transduced cells persisted for more than 1 week and gradually decreased in intensity with cell passages. Secretion of the f-sTeM protein or the f-mChM-I protein in the conditioned media was detected by Western blot with anti-FLAG monoclonal antibodies. A broad ϳ25-kDa immunoreactive band for the mature ChM-I (fmChM-I) and a 21-kDa band for the soluble form TeM (f-sTeM) were detected in the indicated conditioned medium of HRECs, but not in the medium from the control cells (Fig. 5D ). The differences in the protein amount and the molecular weight detected by Western blot enhanced the differences in glycosylation and solubility (hydrophobicity) between f-mChM-I and f-sTeM.
Preservation of the Endothelial Characteristics in HRECs after Adenoviral Infection
HRECs after adenoviral infection fulfilled the established criteria for identification of vascular endothelial cells-that is, they formed a monolayer with cobblestone morphology (Fig. 5C ) and showed positive immunostaining for PECAM (data not shown) and the endothelial-cell-specific uptake of Dil-AcLDL. Almost 100% of the HRECs showed Dil-AcLDL, uptake both with and without adenoviral infection (Fig. 5E ).
Suppression of HREC Proliferation by Autocrine Expression of the f-sTeM Protein or the f-mChM-I Protein
The suppressive effect of the f-sTeM protein and the f-mChM-I protein on VEGF-induced endothelial proliferation was evaluated by measurement of BrdU uptake. BrdU uptake in the wild-type HRECs and the HRECs infected with the empty adenoviral vector (mock) was significantly stimulated by VEGF in a dose-dependent manner, up to 30 ng/mL (Fig. 6A ). In contrast, BrdU uptake in the HRECs transduced with the adenoviral vector, either for expressing the f-sTeM protein or for expressing the f-mChM-I protein, did not increase after the addition of VEGF (Fig. 6A) . To further rule out the nonspecific cytoplasmic effects caused by the adenoviral infection, BrdU uptake of the HUVECs incubated with the conditioned media from the indicated adenoviral-vector-transduced HRECs was evaluated, and similar results were obtained (Fig. 6B) .
Inhibition of Capillary Morphogenesis by Autocrine Expression of the f-sTeM Protein or the f-mChM-I Protein
To explore the in vitro antiangiogenic activity in the C-terminal domain of TeM, capillary-like morphogenesis of vascular endothelial cells on synthetic matrix (Matrigel; BD Labware) and in coculture with dermal fibroblasts were evaluated. Wild-type HRECs and the HRECs infected with the indicated adenoviral vectors were plated on the matrix in the presence of 10 ng/mL 
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VEGF. Under these conditions, wild-type HRECs and mock cells aggregated and elongated to form capillary-like structures within a few hours (Fig. 7A ). In contrast, there was a significant impairment of ability to elongate and to form capillary-like structures in the HRECs expressing f-sTeM or f-mChM-I. The total length of capillary-like structures per field in the adenovirus-transduced HRECs was significantly shorter than that of wild-type and that of mock transfectants (Fig. 7A, bottom) . To further confirm that the suppression of capillary-like formation is essentially attributable to the autocrine response of HRECs to the soluble TeM and ChM-I protein in the conditioned media, capillary formation of HUVECs was tested with the in vitro angiogenesis assay kit by culturing in various conditioned media. Capillary-like structures formed by HUVECs under the stimulation of VEGF were significantly inhibited by the conditioned media derived from f-sTeM and f-mChM-I overexpressing cells. In contrast, no inhibitory activities toward HUVEC capillary formation were observed in the condition medium from the wild-type cultured HRECs or from the mock cells (Fig. 7B ).
DISCUSSION
Growth of new blood vessels is an important event pathologically and physiologically. During the embryonic stages, vasculogenesis and its regression are absolutely necessary for tissue and organ development, such as limb formation and lens development. Because vasculogenesis and its regression are also considered to be regulated and modulated by stimulatory and inhibitory factors, we investigated the expression pattern of TeM, a potent angiogenesis inhibitor, in mouse embryos and young adults. Northern blot analysis demonstrated that the TeM gene is expressed from the embryonic stage and in a tissue-specific manner. In contrast to the expression spike of ChM-I at embryonic day 7, 36 expression of TeM mRNA was initially noted from the late developmental phase of the embryo, a period of skeletal muscle development, suggesting the relationship between TeM gene expression and the formation of skeletal muscle. Other than the tendon and ligament, which are the major expression sites for TeM, 32,33 the eye and skin are newly noted as significant expression sites for TeM mRNA. The expression of both ChM-I and TeM in the eye and their predicted antiangiogenic functions lead us to speculate that ChM-I and TeM also function as antiangiogenic molecules in the eye. In a previous study, we have generated a polyclonal antibody against the human and mouse TeM protein sequence at amino acids 245-252 and successfully detected the recombinant TeM as a transmembrane type glycoprotein by means of cell surface biotinylation and immunoprecipitation. 31 In the current study, the expression of endogenous TeM protein in the eye was confirmed to be comparable with its mRNA distribution detected by Northern blot analysis. The molecular masses of ϳ40 kDa and ϳ45 kDa detected without any small bands for the endogenous TeM protein correspond well with the predicted molecular mass estimated from the full amino acid sequence, indicating that natural TeM protein in the eye may predominantly function as a transmembrane protein on the cell surface. The major band of ϳ40 kDa and the minor band of ϳ45 kDa are variant forms of TeM, due to different glycosylation in vivo. 31, 32 Although the presence of TeM mRNA in the eye has been suggested in previous studies, 31 ,33 the precise mRNA expression sites and the sites of protein expression have never been established. To further examine the site for expression and localization of TeM in the eye, RT-PCR, in situ hybridization, and immunohistochemistry were performed in mouse embryos and young adult mice. In the present study, TeM mRNA was detected in the tendon of the extraocular muscle and the sclerocornea, both of which are categorized as dense connective tissues, together with the tendon, ligament, and epimysium of skeletal muscles. 41 Other than these hypovascular connective tissues, significant TeM mRNA expression is notable in the lens epithelial cells at the equator and the early differentiating secondary lens fiber cells. The anterior cells of the lens vesicle generally proliferate and move toward the equator of the vesicle as lens development progresses. These cells eventually pass through the equatorial region to elongate. 42 It should be noted that the expression of TeM protein most abundantly in the differentiated secondary lens fibers just adjacent to the lens fiber cells that express TeM mRNA correlates well with the cell fate of differentiation in the lens fiber cells. However, TeM mRNA and its translated protein were no longer expressed in any component of the lens from the neonatal stages together with the regression of the vascular networks surrounding the lens (data not shown). We also confirmed the disappearance of TeM expression in lens tissues by RT-PCR in 4-week-old mice. This spatiotemporal expression pattern led us to speculate that TeM in the lens fibers may function as antiangiogenic barriers for preventing vascular network growth into the lens itself during developmental stages of the lens and that expression is self-limited, responding to vascular regression.
In the developing retina, TeM mRNA and protein localization were detected in the inner neural retina and the RPE. As development progressed, TeM mRNA in the inner neural retina was found to be restricted to the ganglion cell layer and to the inner nuclear layer cells. In a previous analysis of adult rat eyes, we have shown that ChM-I mRNA is abundantly expressed in the nonpigment ciliary body, ganglion cell layer, and inner nuclear layer cells of the neural retina and the RPE. 28 Therefore, retina is concluded to be the major tissue where TeM and ChM-I are coexpressed. ChM-I proteins exist as a ϳ37-kDa precursor in its gene-expressing tissues and are then secreted into the aqueous humor and vitreous body as a ϳ25-kDa mature form through processing signals. 28 In contrast to ChM-I, we neither detected any processed form of TeM less than 40 kDa in the tissue extracts from whole eyes nor any positive immunohistochemical signals against TeM in aqueous humor and vitreous body. Together with the absence of processing signal throughout its amino acid sequence, TeM pro- tein is thought to exist predominantly as the transmembrane form on the cell surface and not as the secreted form in the eyes. Because of the antiangiogenic characteristics included in the C terminus of TeM, expression of TeM during the late phase of embryogenesis may contribute to the angiostatic nature of lens and the restricted vascular formation in the retina. Upregulation of VEGF in the aqueous humor and vitreous body has been shown to play an important role in intraocular angiogenesis, such as rubeotic glaucoma and the neovascular membrane proliferation observed in diabetic retinopathy. 6, 43 In a physiological state, expression and localization of VEGF are detectable also in normal ocular vascularized tissues, such as the conjunctiva, iris, retina, and choroid-RPE complex. 13 These features strongly suggest the presence of antiangiogenic agents in the avascular parts of the eye, such as the sclerocornea, aqueous humor ,and vitreous body, for the prevention of vascular invasion. It is of interest that both ChM-I and PEDF are constitutively present in aqueous humor and vitreous body in a high concentration, possibly working to counterbalance the angiogenic stimulators. 21, 28 As the cartilage and vitreous body where ChM-I is expressed is similar in hypovascularity and component (type II collagen), 44 -47 so is the sclerocornea similar to the tendon and ligaments in the three-dimensional network of collagen fibers and hypovascularity categorized as dense connective tissues. 41, 48, 49 The cornea is a transparent avascular tissue. In physiological conditions, the vascular networks of the conjunctiva come close to the limbus and the corneoscleral junction, but never grow into the cornea itself. Sclera per se is also an avascular tissue consisting of the collagenous elastic fibers. Although large blood vessels, such as ciliary arteries penetrate the sclera and construct vascular networks in the chorioretinal layer, the vascular networks never divide within the sclera itself. These findings predict that the existence of angiogenesis inhibitors in the sclerocornea and TeM may be one of the candidates, supported by the revelation in the current study that the C-terminal fragment of TeM (Glu 202 -Val 317 ) and ChM-I (Glu 215 -Val 334 ) effectively inhibited in vitro angiogenesis. The existence of TeM as a transmembrane protein in the sclerocornea and the identification of its antiangiogenic domain on the cell surface may work as an antiangiogenic barrier for the physiological prevention of vascular invasion into these hypovascular tissues.
To the best of our knowledge, TeM and vascular endothelial growth inhibitor (VEGI), a novel member of the tumor necrosis factor family, 50 are the newly identified transmembrane-type angiogenesis inhibitors at present. The antiangiogenic functional region in VEGI was found to be downstream of the transmembrane domain, possibly functioning between the cell-cell or cell-matrix interfaces. Local production of the secreted form VEGI through gene transfer has been reported to suppress tumor growth through the complete arrest of angiogenesis. 50, 51 As we have shown in the present study, the C-terminal fragments (i.e., In summary, we elucidated in the current study the expression and localization pattern of TeM, a transmembrane-type ChM-I-related protein, in mouse eyes and explored the antiangiogenic characteristics in the C-terminal region of TeM by generating a recombinant secreted isoform. Further investigations are needed to clarify fully the mechanism of both TeM and ChM-I for the inhibition of angiogenesis and the safety of using these molecules in clinical applications.
